The Seizmic platform leverages a structure-based approach to identify highly selective antibodies that inhibit dysregulated proteases and other enzymes of interest, Amagma said. The collaboration will allow Innovent to access novel molecules for inflammatory disorders with little to no existing treatment options.

Under the agreement, Innovent will be responsible for the manufacture of the three programs through a phase II study. If Innovent exercises its option, it will also be responsible for R&D and commercialization of each program in China. Amagma will continue to be responsible for global R&D prior to option exercise and ex-China R&D and commercialization thereafter, according to the company.

Amagma is eligible to receive development, approval, and commercial milestones if Innovent exercises the options. Amagma may also receive royalties on net sales of any commercial products in the territory.

Financial details of the agreement were not disclosed.